Fig. 3.
Cost-effectiveness acceptability curve from probabilistic sensitivity analyses for adults aged ≥ 60 years (A) RZV versus no vaccination; (B): RZV versus ZVL. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, RZV adjuvanted herpes zoster subunit vaccine, WTP willingness to pay, ZVL zoster vaccine life